There is evidence that adverse pregnancy outcomes, such as fetal growth restriction, premature delivery, and preeclampsia, are related to reduced blood levels of PSG1 in pregnant women [11,29,30], but there are few reports examining PSG9. This evidence concerns the gene PSG9 and fetal growth restriction.